HomeCompareGIVPY vs ABBV

GIVPY vs ABBV: Dividend Comparison 2026

GIVPY yields 39.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GIVPY wins by $13064844262.03M in total portfolio value
10 years
GIVPY
GIVPY
● Live price
39.34%
Share price
$5.75
Annual div
$2.26
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13064844262.13M
Annual income
$13,001,357,030,571,746.00
Full GIVPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GIVPY vs ABBV

📍 GIVPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGIVPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GIVPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GIVPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GIVPY
Annual income on $10K today (after 15% tax)
$3,343.94/yr
After 10yr DRIP, annual income (after tax)
$11,051,153,475,985,984.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GIVPY beats the other by $11,051,153,475,964,928.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GIVPY + ABBV for your $10,000?

GIVPY: 50%ABBV: 50%
100% ABBV50/50100% GIVPY
Portfolio after 10yr
$6532422131.12M
Annual income
$6,500,678,515,298,259.00/yr
Blended yield
99.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GIVPY
No analyst data
Altman Z
0.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GIVPY buys
0
ABBV buys
0
No recent congressional trades found for GIVPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGIVPYABBV
Forward yield39.34%3.06%
Annual dividend / share$2.26$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$13064844262.13M$102.3K
Annual income after 10y$13,001,357,030,571,746.00$24,771.77
Total dividends collected$13060655215.90M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GIVPY vs ABBV ($10,000, DRIP)

YearGIVPY PortfolioGIVPY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$18,568$7,868.10$11,550$430.00+$7.0KGIVPY
2$47,175$27,307.62$13,472$627.96+$33.7KGIVPY
3$180,160$129,681.79$15,906$926.08+$164.3KGIVPY
4$1,118,462$925,691.14$19,071$1,382.55+$1.10MGIVPY
5$11,938,532$10,741,777.98$23,302$2,095.81+$11.92MGIVPY
6$227,089,016$214,314,786.53$29,150$3,237.93+$227.06MGIVPY
7$7,862,784,807$7,619,799,559.44$37,536$5,121.41+$7862.75MGIVPY
8$501,552,947,841$493,139,768,098.17$50,079$8,338.38+$501552.90MGIVPY
9$59,333,861,272,557$58,797,199,618,367.20$69,753$14,065.80+$59333861.20MGIVPY
10$13,064,844,262,133,382$13,001,357,030,571,746.00$102,337$24,771.77+$13064844262.03MGIVPY

GIVPY vs ABBV: Complete Analysis 2026

GIVPYStock

Grupo de Inversiones Suramericana S.A. operates in the financial services, industry, and corporate venture sectors in Colombia and internationally. The company offers general and life insurance, as well as reinsurance; pension, saving, investment, and asset management services; investment funds; annuities; severance pay and complementary services; health plans; occupational hazards; and business, consumer, insurance, investment, offshore, private, and government banking, as well as treasury products. It also produces cement, concrete, and aggregates; provides processed foods, such as cold cuts, confectionery, chocolates, coffees, ice cream, pasta, and consumer foods; and offers power generation and distribution, real estate, road and airport concessions, and business support services. In addition, the company provides a technological solution to manage human talent information for companies; a digital marketplace for mortgage sector; a platform for engagement, marketing, sale, and administration of financial products; a health technology platform; tools to manage prevention and wellbeing programs; web and mobile platform based on artificial intelligence; platform for on-demand insurance; and risk capital fund for early-stage and growing technology companies. Further, it offers integrated information, technology, and knowledge solutions; and residential, functional conditioning, and rehabilitation services for the elderly. Additionally, the company provides data processing and leasing computer equipment, consultancy and advisory, promotion, and marketing services; management consultancy services; medical, paramedical, dental, and diagnostic aid services; risk management, telecommunication, and outsourcing services; and vehicle inspection, repair, purchase, and selling services, as well as acts as securities brokers; and purchases and sells securities. The company was incorporated in 1997 and is headquartered in Medellin, Colombia.

Full GIVPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GIVPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GIVPY vs SCHDGIVPY vs JEPIGIVPY vs OGIVPY vs KOGIVPY vs MAINGIVPY vs JNJGIVPY vs MRKGIVPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.